Emergent BioSolutions begins phase 3 trial of CHIKV VLP vaccine candidate
Emergent BioSolutions said that it has dosed the first participant in a phase 3 clinical trial of CHIKV VLP — the company’s single-dose chikungunya vaccine candidate. The American biopharma company will test the safety and immunogenicity of the investigational chikungunya virus (CHIKV) virus-like particle (VLP) vaccine. According to Emergent BioSolutions, CHIKV VLP is the only […]